TRPM4 controls insulin secretion in pancreatic beta-cells

Henrique Cheng1, Andreas Beck, Pierre Launay

  • 1Laboratory of Cell and Molecular Signaling, Center for Biomedical Research at The Queen's Medical Center and John A. Burns School of Medicine at the University of Hawaii, 1301 Punchbowl Street, UHT 8, Honolulu, HI 96813, USA.

Cell Calcium
|June 30, 2006
PubMed

Insights

Transient Receptor Potential Melastatin 4 (TRPM4) channels in pancreatic beta-cells regulate insulin secretion by controlling cell depolarization. TRPM4

Area of Science:

  • Cellular physiology
  • Ion channel function
  • Endocrinology

Background:

  • Transient Receptor Potential Melastatin 4 (TRPM4) channels are calcium-activated non-selective cation channels implicated in cell depolarization.
  • In excitable cells, TRPM4 channels may modulate calcium influx by influencing voltage-dependent calcium channel activation.

Purpose of the Study:

  • To investigate the role of TRPM4 channels in insulin-secreting cells.
  • To characterize TRPM4 channel activity and its regulation in pancreatic beta-cells.

Main Methods:

  • Electrophysiological recordings in INS-1 cells and HEK-293 cells.
  • Expression of dominant-negative TRPM4 constructs.
  • Measurement of insulin secretion in response to glucose and arginine vasopressin.
  • Cell capacitance measurements and FM1-43 dye uptake assays.

Main Results:

  • INS-1 cells natively express functional TRPM4 channels that generate calcium-activated depolarizing currents.
  • Suppression of TRPM4 activity significantly reduced glucose- and arginine vasopressin-stimulated insulin secretion.
  • TRPM4 channel recruitment to the plasma membrane occurs in two phases: immediate plasma membrane activation and a secondary phase involving vesicle recruitment during exocytosis.

Conclusions:

  • TRPM4 channels play a critical role in regulating membrane potential and electrical activity in secretory cells.
  • Dynamic translocation of TRPM4 from vesicular stores to the plasma membrane via calcium-dependent exocytosis is a key regulatory mechanism for cellular electrical activity and insulin secretion.

Related Concept Videos

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...